Antibe Therapeutics is a biotechnology company with a focus on developing innovative treatments for inflammation. The company aims to cater to the non-addictive management of chronic and post-surgical pain, offering significant potential for major markets. Leading the drug pipeline is a late-stage Phase 2 clinical trial that promises unparalleled safety in treating chronic pain, a condition that affects over 50 million Americans. Furthermore, the company aims to address the worldwide opioid crisis by developing a second pipeline drug to replace opioids in pain management. Finally, with a third daily aspirin, Antibe Therapeutics seeks to provide a safer option that delivers anti-stroke and anti-cancer benefits without harming the digestive tract.